7W3 Stock Overview
Operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Acotec Scientific Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.93 |
| 52 Week High | HK$1.61 |
| 52 Week Low | HK$0.70 |
| Beta | 0.23 |
| 11 Month Change | 5.68% |
| 3 Month Change | 10.71% |
| 1 Year Change | -34.97% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -51.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7W3 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 1.6% | -3.5% | 0.8% |
| 1Y | -35.0% | 2.2% | 6.1% |
Return vs Industry: 7W3 underperformed the German Medical Equipment industry which returned 2.2% over the past year.
Return vs Market: 7W3 underperformed the German Market which returned 6.1% over the past year.
Price Volatility
| 7W3 volatility | |
|---|---|
| 7W3 Average Weekly Movement | 9.3% |
| Medical Equipment Industry Average Movement | 4.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 7W3 has not had significant price volatility in the past 3 months.
Volatility Over Time: 7W3's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 638 | Jing Li | www.acotec.cn |
Acotec Scientific Holdings Limited operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China, Europe, and internationally. The company’s products include AcoArt Orchid & Dhalia, a paclitaxel DCB used to prevent stenosis or occlusion in superficial femoral artery (SFA) and popliteal artery (PPA) for the treatment of lower extremity artery disease (LEAD) with a vascular interventional approach; and AcoArt Tulip & Litos, a paclitaxel coated DCB used to prevent stenosis or occlusion in below-theknee (BTK) arteries for the treatment of chronic limb-threatening ischemia with a vascular interventional approach. It also offers devices targeting vascular surgery, including AcoArt Iris & Jasmin; AcoArt Lily & Rosmarin; Peripheral Aspiration System (AcoStream); Radiofrequency Ablation System (AcoArt Cedar); Peripheral Support Catheter (Vericor); The PTA Balloon (P-Conic); and 2nd Gen Peripheral Aspiration System (2nd Generation AcoStream).
Acotec Scientific Holdings Limited Fundamentals Summary
| 7W3 fundamental statistics | |
|---|---|
| Market cap | €307.33m |
| Earnings (TTM) | €1.84m |
| Revenue (TTM) | €60.25m |
166.8x
P/E Ratio5.1x
P/S RatioIs 7W3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7W3 income statement (TTM) | |
|---|---|
| Revenue | CN¥473.85m |
| Cost of Revenue | CN¥96.43m |
| Gross Profit | CN¥377.42m |
| Other Expenses | CN¥362.93m |
| Earnings | CN¥14.49m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.046 |
| Gross Margin | 79.65% |
| Net Profit Margin | 3.06% |
| Debt/Equity Ratio | 0.8% |
How did 7W3 perform over the long term?
See historical performance and comparison